Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study

1. Klastersky JA. Use of imipenem as empirical treatment of febrile neutropenia. Int J Antimicrob Agents 2003; 21: 393–402. 2. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–51. 3. Mouton JW, Touzw DJ, Horrevorts AM et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39: 185–201. 4. Ariano RE, Nyhlen A, Donnelly JP et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39: 32–8. 5. Lortholary O, Lefort A, Tod M et al. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 2008; 8: 612–20. 6. Lamoth F, Buclin T, Csajka C et al. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother 2009; 53: 785–7. 7. Navas D, Caillon J, Batard E et al. Trough serum concentrations of b-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic/pharmacodynamic properties of b-lactams. Int J Antimicrob Agents 2006; 27: 102–7. 8. Giannoni E, Moreillon P, Cotting J et al. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob Agents Chemother 2006; 50: 2563–8.